

Supplementary Table 3. Multivariate analysis of overall survival after the administration of immune checkpoint inhibitor considering PD-L1 any positivity

Parameter	Univariate analysis			Multivariate analysis		
	HR	95% CI	p value	HR	95% CI	p value
Age	0.99	0.96–1.03	0.681	1.04	0.99–1.10	0.126
Sex (female as reference)	0.40	0.19–0.82	0.013 ^a	3.41	0.35–33.4	0.291
Smoking status (never smoker as reference)						
Current/former smokers	0.40	0.19–0.83	0.014 ^a	0.08	0.01–0.86	0.037 ^a
Histologic subtype (adenocarcinoma as reference)			0.163			0.095
Squamous	0.76	0.34–1.66	0.484	1.47	0.54–4.03	0.456
Others	0.31	0.09–1.06	0.061	0.31	0.08–1.13	0.075
EGFR mutation (absent as reference)	2.24	1.05–4.79	0.038 ^a	2.37	0.78–7.20	0.128
No. of prior chemotherapy regimen (1 or 2 as reference)						
3 or more	2.22	1.09–4.53	0.029 ^a	1.40	0.48–4.09	0.543
ECOG (0 or 1 as reference)						
ECOG 2 or more	2.72	1.36–5.53	0.006 ^a	2.61	1.05–6.51	0.040 ^a
PD-L1 any positivity (negative as reference)	0.43	0.20–0.93	0.427	0.31	0.10–0.90	0.031 ^a

PD-L1, programmed death-ligand 1; HR, hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group.

^ap < 0.05